Amanda Groome
Primary Care · Greenville, SCNPI 1013217850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 362 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 362 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$902
- Axsome Therapeutics, Inc.$828
- Vanda Pharmaceuticals Inc.$481
- Teva Pharmaceuticals USA, Inc.$458
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,55999%
- Education$1221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 88 | $1,872 |
| Otsuka America Pharmaceutical, Inc. | 52 | $1,125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $902 |
| Axsome Therapeutics, Inc. | 28 | $828 |
| Vanda Pharmaceuticals Inc. | 17 | $481 |
| Teva Pharmaceuticals USA, Inc. | 16 | $458 |
| Alkermes, Inc. | 15 | $379 |
| Neurocrine Biosciences, Inc. | 18 | $336 |
| Lundbeck LLC | 17 | $322 |
| Johnson & Johnson | 13 | $310 |
| Supernus Pharmaceuticals, Inc. | 7 | $283 |
| E.r. Squibb & Sons, L.L.C. | 5 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $252 |
| Sunovion Pharmaceuticals Inc. | 7 | $141 |
| Avanir Pharmaceuticals, Inc. | 2 | $139 |
| Acadia Pharmaceuticals Inc | 6 | $137 |
| Biogen | 2 | $103 |
| Corium, LLC | 4 | $68 |
| Tris Pharma Inc | 4 | $68 |
| TMS Neurohealth Centers Inc. | 1 | $39 |
| Bausch Health US, LLC | 2 | $35 |
| Almatica Pharma LLC | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $20 |
| Neos Therapeutics, LP | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,681 in reported general payments places this provider in the 95th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $211,704 |
| Austedo XrDeutetrabenazine | 16 | $112,681 |
| RexultiBrexpiprazole | 52 | $91,268 |
| VraylarCariprazine Hcl | 41 | $55,763 |
| TrintellixVortioxetine Hydrobromide | 17 | $13,900 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $8,090 |
| Aripiprazole | 90 | $6,796 |
| Ramelteon | 28 | $5,214 |
| BelsomraSuvorexant | 12 | $4,848 |
| Vilazodone Hcl | 22 | $2,333 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 66 | $2,263 |
| Duloxetine Hcl | 84 | $1,711 |
| Doxepin Hcl | 65 | $1,615 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 40 | $1,529 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 41 | $1,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $336 | $211,70427 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $458 | $112,68116 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,125 | $91,26852 claims |
| AbbVieVraylar | $1,872 | $55,76341 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $252 | $21,99038 claims |
| Almatica Pharma LLCSertraline Hcl | $32 | $43035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 115 primary care providers in South Carolina.
Other primary care in Greenville
- Sarah TomashefskiGreenville$23K
- Taylor ClarkGreenville$1K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
- Heather MartinSeneca$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.